Randomized controlled trial of postoperative radiotherapy and short- term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer

British Journal of Surgery

Volumn 84, Issue 8, 1997, Pages 1130-1135

  Tveit, K M ^a,b   Guldvog, I ^a   Hagen, S ^b   Trondsen, E ^c   Harbitz, T ^d   Nygaard, K ^b   Nilsen, J B ^e   Wist, E ^f   Hannisdal, E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e TELEMARK HOSPITAL   (Norway)

^f Tromsø Regional Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; VOMITING;

EID: 0030805013     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840827     Document Type: Article

References (26)

1. Gerard A, Buyse M, Nordlinger B et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988; 208: 606-14.
2. Stockholm Rectal Cancer Group. Preoperative short-term radiation therapy in operable rectal carcinoma: a randomized trial. Cancer 1990; 66: 49-55.
3. Dahl O, Horn A, Morild I et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway. Cancer 1990; 66: 2286-94.
4. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988; 259: 3571-8.
5. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21-9.
6. Galloway DJ, Cohen AM, Shank B, Friedman MA. Adjuvant multimodality treatment of rectal cancer. Br J Surg 1989; 76: 440-7.
7. Balslev IB, Pedersen M, Teglbjaerg PS et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicentre study. Cancer 1986; 58: 22-8.
8. Rosenthal SA, Trock BJ, Coia LR. Randomized trials of adjuvant radiation therapy for rectal carcinoma: a review. Dis Colon Rectum 1990; 33: 335-43.
9. O'Connell MJ, Gunderson LL. Adjuvant therapy for adenocarcinoma of the rectum. World J Surg 1992; 16: 510-15.
10. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465-72.
11. Douglass HO Jr, Moertel CG, Mayer RJ et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 315: 1294-5 (Letter).
12. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-15.
13. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-7.
14. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549-57.
15. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
16. Murray GD. Statistical aspects of research methodology. Br J Surg 1991; 78: 777-81.
17. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society B 1972; 34: 187-220.
18. Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP Statistical Software Manual. Berkeley, California: University of California Press, 1990.
19. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5: 85-91.
20. Nakajima Y, Miyamoto T, Tanabe M, Watanabe I, Terasima T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res 1979; 39: 3763-7.
21. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982; 8: 1923-33.
22. Smalley SR, Kimler BF, Evans RG, Dalziel WC. Mammalian cell heterogeneity to modulation by 5-fluorouracil. Int J Radiol Oncol Biol Phys 1990; 19(Suppl 1): 184.
23. Smalley SR, Kimler BF, Evans RG. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 20: 207-11.
24. Rich TA, Murray D. Antimetabolites. In: John MJ, Flam MS, Legha SS, Phillips TL, eds. Chemoradiation: An Integrated Approach to Cancer Treatment. Philadelphia, Pennsylvania: Lea and Febiger, 1993: 79-89.
25. Spears CP, Gustavsson BG, Frøsing R. Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration. Invest New Drugs 1989; 7: 27-36.
26. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-60.